In vivo evaluation of snake fruit Kombucha as hyperglycemia therapeutic agent - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Food Research Journal Année : 2018

In vivo evaluation of snake fruit Kombucha as hyperglycemia therapeutic agent

Résumé

This research was a part of development of functional beverage through fermentation of snake fruit juice with Kombucha consortium. The aim of this research was to study on in vivo evaluation of snake fruit Kombucha as hyperglycemia therapeutic agent. The snake fruit (Salak Suwaru cultivar) juice was fermented for 14 days with the Kombucha consortium. Streptozotocin induced diabetic rats were used in the in vivo evaluation. The snake fruit Kombucha was orally administerred at different level for 28 days. The results revealed the treatment showed a significant fasting plasma glucose reduction in a range of 31-59%, consistent with improving of blood serum superoxide dismutase activity and malondialdehyde level. Immunohistochemical staining of pancreatic tissue proved a regeneration of the pancreatic beta cells in the groups of snake fruit Kombucha treatment compared to control group. Snake fruit Kombucha was proven as a hyperglycemia therapeutic agent in diabetic rats model.
Fichier non déposé

Dates et versions

hal-01886460 , version 1 (02-10-2018)

Identifiants

  • HAL Id : hal-01886460 , version 1
  • PRODINRA : 426088
  • WOS : 000427099200060

Citer

E. Zubaidah, T. E. Apriyadi, U. Kalsum, E. Widyastuti, T. Estiasih, et al.. In vivo evaluation of snake fruit Kombucha as hyperglycemia therapeutic agent. International Food Research Journal, 2018, 25 (1), pp.453-457. ⟨hal-01886460⟩
27 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More